BioMarin Pharmaceutical Inc. Discontinues VOXZOGO Development for Noonan Syndrome

What Happened

• On September 15, 2026, BioMarin Pharmaceutical Inc. announced via an 8-K that it has decided to discontinue development of VOXZOGO for children with Noonan syndrome. The company said the decision followed an assessment of factors including the feasibility of the study and the current treatment landscape. BioMarin stated the decision was not related to the safety or efficacy of VOXZOGO and uses its investor relations website for material disclosures.

Key Details

• Filing date: September 15, 2026 (Form 8-K, Item 8.01 — Other Events).
• Program: VOXZOGO (clinical development for children with Noonan syndrome).
• Reason cited: considerations of study feasibility and the current treatment landscape.
• Company note: decision explicitly “not related to the safety or efficacy” of VOXZOGO; disclosures made via BioMarin’s investor relations site.

Why It Matters

• This is a material pipeline change: discontinuing a development program can affect BioMarin’s future clinical pipeline prospects and how investors value the company’s R&D portfolio.
• The 8-K does not disclose any financial impact or changes to guidance; investors should watch for follow-up disclosures (press releases, future SEC filings) for details on financial effects, resource reallocation, or strategy updates.
• Because the company clarified the decision was not due to safety or efficacy, the change reduces the likelihood of safety-related regulatory concerns tied to this program but removes the potential future revenue opportunity from this indication.